ClinicalTrials.gg
CompletedNCT02427165Updated Sep 9, 2016

Comparison of RPL554 With Placebo and Salbutamol in Asthmatic Patients

A Phase 2 interventional study of RPL554 and Salbutamol in Asthma, sponsored by Verona Pharma plc. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-09-09.

Sponsored by Verona Pharma plc (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies in Asthma by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Asthma · Merck & Co., Inc.

Enrollment
11th of 23
29 · median 27
Started
2015
the only one that year
Phase 2
12 of 23
none open now
Registered
22nd of 23
by date

Among the 23 studies in Asthma by Merck & Co., Inc, this one is the 11th largest by enrollment, is the only one that started in 2015, is one of 12 in phase 2, and was the 22nd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 23 studies in Asthma by Merck & Co., Inc is open now. The open studies under Asthma, anywhere →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 23 studies in Asthma by Merck & Co., Inc as a file.
02

Study summary

The number of people with of asthma and allergy is still increasing and a large number of patients still do not have their asthma well controlled. There is therefore a need for new asthma treatments that work well and have less side effects. The study compares a new experimental drug RPL554 with a marketed asthma drug (salbutamol) and placebo.

Read the detailed description

A seven way crossover study to investigate the pharmacodynamics, pharmacokinetics, safety and tolerability of inhaled RPL554 compared to salbutamol and placebo in patients with mild to moderate chronic asthma.

Salbutamol is a marketed beta-2 agonist typically used to treat bronchospasm (due to any cause, allergen asthma or exercise-induced), as well as chronic obstructive pulmonary disease but has associated dose-related systemic side effects.

RPL554 is a dual PDE3 and PDE4 inhibitor that has bronchodilatory and anti-inflammatory actions and also the potential to stimulate increases in mucociliary clearance via its proven ability to activate CFTR. Four different doses of RPL554 will be compared with placebo and a two doses of salbutamol as benchmarks for bronchodilation and systemic side effects.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provided written
  • Males agree not to donate sperm and either be abstinent or use adequate . Females to be or surgically sterile
  • Non-smoker or ex-smoker >6 months
  • Diagnosed asthma for at least 6 months
  • Pre-bronchodilator ≥60% and ≤90% of predicted normal value and ≥1.5 L at screening
  • Increase in FEV1 of 15% within 30 minutes after a 2.5mg dose of nebulised salbutamol
  • Systolic blood pressure 90 to 145 mmHg, diastolic blood pressure 50 to 90 mmHg and heart rate 45 to 80 beats per minute (bpm) after resting for 5 minutes in a supine position (average from two measurements)
  • Capable of withdrawing from LABAs, LAMAs and SAMAs before screening and during study and SABAs before screening and for 8 hours before each dose

Exclusion criteria

Exclusion Criteria:

  • Asthma exacerbation in the last 3 months
  • Any prior life threatening episode of asthma (intensive care admission)
  • Any disease or disorder or clinically relevant screening result
  • interval >450 ms or QT interval >500 ms or other abnormality in
  • History of ischemic heart disease or heart failure. History of recurrent or current clinically significant arrhythmia or ECG abnormality as judged by the investigator
  • Treatment with systemic glucocorticosteroids within 30 days before screening
  • A suspected/manifested infection according to WHO risk classification 2, 3 or 4
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
29 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Single dose of nebulised placebo solution

    Drug: Placebo

  • Experimental
    RPL554 Dose 1

    0.4 mg single dose nebulised RPL554

    Drug: RPL554

  • Experimental
    RPL554 Dose 2

    1.5 mg single dose nebulised RPL554

    Drug: RPL554

  • Experimental
    RPL554 Dose 3

    6 mg single dose nebulised RPL554

    Drug: RPL554

  • Experimental
    RPL554 Dose 4

    24 mg single dose nebulised RPL554

    Drug: RPL554

  • Active comparator
    Salbutamol Dose 1

    2.5 mg single dose nebulised salbutamol

    Drug: Salbutamol

  • Active comparator
    Salbutamol Dose 2

    7.5 mg single dose nebulised salbutamol

    Drug: Salbutamol

Interventions

  • DrugRPL554

    A dual PDE3 and PDE4 inhibitor

    Also known as: VMX554, VRP554

  • a beta-2 receptor agonist

  • DrugPlacebo

    RPL554 placebo containing no active ingredients

06

What researchers measure

Primary outcomes

  1. Spirometry

    FEV1

    Time frame: 12 hours

Secondary outcomes

  1. Spirometry

    FEV1

    Time frame: 4, 6 and 8 hours

  2. Systemic pharmacodynamic effect on blood pressure

    Supine blood pressure in the 4 hours after nebulisation

    Time frame: 4 hours

  3. Systemic pharmacodynamic effect on pulse rate

    Supine Pulse rate in the 4 hours after nebulisation

    Time frame: 4 hours

  4. Systemic pharmacodynamic effect on ECG heart rate

    ECG heart rate in the 4 hours after nebulisation

    Time frame: 4 hours

  5. Vital signs (Supine pulse rate)

    Supine pulse rate

    Time frame: 12 hours

  6. Vital signs (Supine blood pressure)

    Supine systolic and diastolic blood pressure

    Time frame: 12 hours

  7. ECG

    12-lead ECG parameters

    Time frame: 12 hours

  8. Pharmacokinetics (AUC)

    RPL554 AUC

    Time frame: 12 hours

  9. Pharmacokinetics (Cmax)

    RPL554 Cmax

    Time frame: 12 hours

  10. Pharmacokinetics (tmax)

    RPL554 tmax

    Time frame: 12 hours

  11. Pharmacokinetics (half life)

    RPL554 half life

    Time frame: 12 hours

  12. Pharmacokinetics (MRT)

    RPL554 MRT

    Time frame: 12 hours

07

Study locations

2 sites
  • Skane University Hospital
    Lund, Sweden
  • Celerion
    Belfast, United Kingdom
08

References and documents

Publications

  • Bjermer L, Abbott-Banner K, Newman K. Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma. Pulm Pharmacol Ther. 2019 Oct;58:101814. doi: 10.1016/j.pupt.2019.101814. Epub 2019 Jun 14. PubMed 31202957 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2015, a primary completion of Nov 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2015
First posted
Apr 27, 2015
Start
Apr 2015
Primary completionActual
Nov 2015
CompletionActual
Nov 2015
Last update
Sep 9, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02427165
Lead sponsor
Verona Pharma plc
Responsible party
Sponsor
First posted
Apr 27, 2015
Start date
Apr 2015
Primary completion
Nov 2015
Completion
Nov 2015
Last update
Sep 9, 2016

Study contacts

Lief Bjermer
principal investigator · Skane University Hospital, Sweden
Johnston Stewart
principal investigator · Celerion, Northern Ireland

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ensifentrine

Start the discussion